Author: Ravi Shankar

• The Executive Board is expanded to five members: Olivier Lacombe, Didier Morin and Lionel Seltz join Patrick Alexandre and Isabelle Liebschutz
• A leadership team covering the entire value chain: pharmaceutical development, industrial operations, quality and regulatory affairs, finance and corporate
• CROSSJECT US strengthens its regulatory leadership with the appointment of David Pudwill as Vice President, Regulatory & Scientific Affairs

DIJON, FRANCE, September 25, 2026 – 07h30 (CEST) – CROSSJECT (ISIN: FR0011716265; Euronext Growth: ALCJ), a Specialty Pharma company developing innovative solutions for emergency situations based on its proprietary ZENEO® needle-free auto-injector technology, today announces that its Supervisory Board, meeting on September 24, 2026, unanimously appointed Olivier Lacombe, Didier Morin and Lionel Seltz as members of the Executive Board. Their appointments are effective immediately, and their terms will expire on February 17, 2029.

“In 2025, the Board streamlined the Executive Board around a single priority: the registration of ZEPIZURE®. The priority now is to industrialise and deliver. We are therefore expanding the Executive Board so that the key skills for this new phase are represented where decisions are made. Drawn from the existing team, these three appointments give CROSSJECT a complete, experienced and immediately operational leadership,” said Philippe Monnot, Chairman of the Supervisory Board.

The Executive Board of CROSSJECT now comprises Patrick Alexandre, Chairman, Isabelle Liebschutz, Quality and Regulatory Director and Qualified Person, Olivier Lacombe, Pharmaceutical Development Director, Didier Morin, Industrial Director, and Lionel Seltz, Chief Financial Officer. The three new members continue to exercise their current operational responsibilities.

A governance structure built for the execution phase

In February 2025, the Supervisory Board narrowed the Executive Board to two members in order to focus decision-making on the final stages of ZEPIZURE®’s registration with the FDA (U.S. Food and Drug Administration). As that work advances, CROSSJECT is preparing for a phase of a different nature: scaling up its industrial operations, preparing initial deliveries and building its commercial presence in the United States.

This phase simultaneously mobilises pharmaceutical development, manufacturing and supply chain, regulatory compliance and the Group’s financial structure. The expansion of the Executive Board responds directly to that shift: every critical link, from the molecule to delivery to the patient, is now represented within the body that leads the Company. It also reflects the structuring of the Group around its French and U.S. entities.

The Executive Board now brings together 140 years of combined experience in pharmaceuticals, medical devices and industrial operations.

Olivier Lacombe, Pharmaceutical Development Director, joined CROSSJECT in 2021. He brings 21 years of experience in pharmaceutical development, gained notably at Laboratoires FOURNIER, ABBOTT, SOLVAY and INVENTIVA. He leads the pharmaceutical development of the ZENEO® platform and the pharmaceutical quality documentation of the product portfolio.

Didier Morin, Industrial Director, joined CROSSJECT in 2023. He brings 30 years of industrial experience, gained notably at IDS and AXESS VISION. He leads the Group’s industrial operations, the scale-up of its production sites and its supply chain.

Lionel Seltz, Chief Financial Officer, joined CROSSJECT in January 2026. He brings 25 years of international financial experience in life sciences and healthcare, gained at CEGEDIM, at IQVIA/IMS Health in Asia-Pacific and within the MARS GROUP, as well as serving as Chief Financial Officer of three listed medtech and biotech companies. His remit covers finance and treasury, financial communication, legal and governance, intellectual property, U.S. government contracts, human resources and information systems.

CROSSJECT US strengthens its regulatory leadership

Alongside the strengthening of its governance, CROSSJECT continues to build its U.S. organisation.
David Pudwill has joined CROSSJECT US as Vice President, Regulatory & Scientific Affairs, and reports to Tony Tipton, Chief Operating Officer of CROSSJECT US, who leads the U.S. entity’s operations and will support David in carrying out his regulatory and scientific responsibilities.

David Pudwill brings approximately 20 years of experience in regulatory affairs, product development, quality and clinical strategy, including nine years with the FDA (U.S. Food and Drug Administration), where he served as a lead medical device reviewer and as a branch chief. His experience spans medical devices, pharmaceuticals, biologics and drug-device combination products, with particular expertise in complex FDA pathways and cross-center programs. That profile maps directly onto the combination nature of the ZENEO® platform. He holds a Master of Mechanical Engineering from Johns Hopkins University and a Bachelor’s Degree in Biomedical Engineering from Case Western Reserve University.

At CROSSJECT US, David Pudwill leads the U.S. regulatory, clinical and scientific strategy for ZEPIZURE® and future products based on the ZENEO® platform. He supports the Company’s engagement with the FDA, BARDA and other U.S. government and strategic partners, and strengthens coordination between the French and U.S. teams.

“CROSSJECT is entering an important phase of execution as it scales manufacturing and prepares for commercialization of ZENEO-based products. I look forward to helping CROSSJECT continue to build its relationships with BARDA, the FDA and other strategic partners as it advances ZEPIZURE® through the FDA authorization process and prepares, subject to that authorization, to deliver product to the U.S. Strategic National Stockpile,” said David Pudwill, Vice President, Regulatory & Scientific Affairs, CROSSJECT US.

“CROSSJECT is changing in nature: we are moving from a development company to a company that manufactures, delivers and commercialises. The people who built ZENEO® and ZEPIZURE® are the ones who should lead its industrialisation and launch. By expanding the Executive Board and strengthening our regulatory team in the United States, we are giving ourselves the means to execute this transition with the rigour our partners expect, BARDA and the FDA first among them,” said Patrick Alexandre, Chairman of the Executive Board.

Attachment

• 09.CP-NOMINATION-DU-DIRECTOIRE-EN

Cash and cash equivalents of €12.3 million as of June 30, 2026, a 2.4-fold increase compared to December 31, 2025 (€5.1 million), following the €15 million capital increase completed in May.

Shareholders’ equity returned to positive territory at €3.0 million (compared to −€4.9 million as of December 31, 2025), and adjusted net financial debt was more than halved to €7.8 million (from €17.4 million).

BARDA revenue totaled €2.5 million (€6.6 million in H1 2025), as H1 2025 saw a concentration of validation activities and a clinical trial; H1 2026 returned to a pace representative of ongoing development activity. Operating expenses remained stable at €10.3 million, excluding depreciation, provisions, and disposal-related items (€10.3 million in H1 2025).

Net income of −€8.6 million (−€4.9 million in H1 2025): H1 2025 saw two non-recurring milestones—the validation campaign and a clinical trial.

Post-closing: BARDA contract extended through 2030 and increased to $48.0 million (+$4.7 million in non-dilutive funding).

DIJON, France – September 25, 2026 (7:30 a.m. CEST) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceutical company developing products for emergency situations based on its proprietary ZENEO® needle-free autoinjector technology, currently in the advanced stages of development and regulatory approval for ZEPIZURE®, an injectable treatment for epileptic seizures, today published its results for the first half of the year ended June 30, 2026.

Financial statements approved by the Executive Board on September 24, 2026, and reviewed by the Supervisory Board on September 24, 2026. These financial statements have not been subject to a limited review by the statutory auditors.

(in M€)	H1 2026	H1 2025
Operating revenue	4.8	8.0
of which BARDA	2.5	6.6
Operating income	−8.9	−5.1
Net income	−8.6	−4.9
	06/30/26	12/31/25
Cash	12.3	5.1
Equity	3.0	−4.9
Adj. net financial debt	7.8	17.4

“The first half of 2026 was devoted to strengthening our financial foundations. The €15 million capital increase completed in May enabled us to return to positive equity and reduce our net debt by more than half. Our half-year results reflect a lower level of BARDA revenue compared to 2025, while our operating expenses remain under control. Alongside BARDA, our teams remain fully focused on the registration of ZEPIZURE® and on preparing our first shipments.”

Patrick ALEXANDRE, Chairman of the Executive Board of CROSSJECT

“Our priority is clear: to manage cash flow with the utmost rigor and to secure the Company’s financing—giving priority to non-dilutive resources—until ZEPIZURE® generates its first commercial revenue.”

Lionel SELTZ, Chief Financial Officer

Highlights of the First Half of 2026

A Significant Strengthening of Equity

On May 22, 2026, CROSSJECT completed a capital increase reserved for a specific category of investors, accompanied by an issuance of stock subscription warrants (BSA), for a total gross amount of €15 million: 6,441,300 new shares were issued at a price of €1.704, and 6,441,300 stock warrants were subscribed at a price of €0.626. Maxim Group LLC acted as the exclusive placement agent. If all stock warrants are exercised (four warrants entitling the holder to subscribe for five shares at a price of €2.68), the Company could receive an additional amount of up to €21.6 million.

During the half-year, €2.07 million in convertible bonds (HCM) were converted into shares, contributing to the reduction in bond debt. As of June 30, 2026, the share capital consists of 60,023,823 shares.

Debt Reduction Underway

The Company repaid €1.8 million in bank loans and €1.2 million in repayable advances during the half-year.

Regulatory and Industrial Progress on ZEPIZURE®

During the first half of the year, CROSSJECT continued, in close collaboration with BARDA, the regulatory work related to ZEPIZURE®. Discussions took place at a steady pace and at a high technical level, focusing in particular on the dossier documentation as well as the accompanying manufacturing and qualification elements. This work is actively ongoing. In accordance with the communication strategy agreed upon with its U.S. partner, the Company does not disclose the timeline for the authorization process, which is managed by BARDA. Following an inspection, the ANSM issued a new certificate of compliance with Good Manufacturing Practices for all pharmaceutical operations carried out by CROSSJECT. The company also maintains its ISO 13485 certification for all of its sites in France.

On the industrial front, the Company continued to prepare its production facilities and supply chain for the first deliveries: it continued the investments already underway at its sites, carried out equipment qualification work, and strengthened its manufacturing partnerships. These investments are reflected on the balance sheet as €3.9 million in assets under construction as of June 30, 2026.

Organization and Visibility with the Financial Community

CROSSJECT strengthened its management team with the appointment of Lionel SELTZ as Chief Financial Officer that joined in January 2026. Portzamparc (BNP Paribas Group) initiated coverage of the stock in February 2026: CROSSJECT is now covered by five research firms (Alpha Value, Invest Securities, Maxim Group, ODDO BHF, and Portzamparc).

Analysis of First-Half 2026 Results

Operating revenue totaled €4.8 million, compared with €8.0 million in the first half of 2025 (−40%). Revenue from the BARDA contract amounted to €2.5 million, compared with €6.6 million a year earlier. This difference is timing-related and primarily reflects the exceptional nature of the first half of 2025, which saw the completion of two major program milestones: the validation campaign and the conduct of a clinical study. These milestones had driven activity—and thus the expenses reimbursed by BARDA—well above the usual pace. In line with the program schedule, the first half of 2026 returned to a level representative of ongoing development activity, similar to that of the first half of 2024. BARDA-funded activity is expected to increase again as the program moves through its next milestones, with the contract’s performance period now extended to June 2030 under Modification 4. Capitalized production (development costs) totaled €1.2 million (€1.5 million). Other income (€1.3 million, compared with €0.1 million) includes €0.6 million in proceeds from the disposal of fixed assets related to the refinancing of industrial projects and €0.7 million in reversals of provisions, including €0.4 million related to inventory.

Operating expenses totaled €13.7 million, compared with €13.2 million (+4%). This increase stems primarily from the net book value of disposed fixed assets (€0.5 million), which was not present in the first half of 2025 and was offset by the corresponding proceeds from the disposal. Depreciation, amortization, and provisions remained stable at €2.9 million (€2.9 million). Excluding depreciation, amortization, and provisions, as well as disposal-related items, operating expenses totaled €10.3 million, unchanged from the first half of 2025 (€10.3 million): other purchases and external expenses decreased by 4% to €5.1 million, and personnel expenses remained stable at €4.0 million.

Operating income came in at −€8.9 million, compared to −€5.1 million in the first half of 2025. This change mainly reflects lower BARDA revenue following an exceptional first half of 2025. The financial result improved to −€0.9 million (−€1.1 million). After accounting for the research tax credit (€1.3 million, compared to €1.6 million), net income came in at −€8.6 million, compared to −€4.9 million in the first half of 2025.

A Significantly Strengthened Financial Structure

As of June 30, 2026, total assets amounted to €35.6 million, compared to €30.4 million as of December 31, 2025. Shareholders’ equity returned to positive territory at €3.0 million, compared to −€4.9 million as of December 31, 2025, driven by the May 2026 capital increase and bond conversions, net of the half-year loss. Equity, including conditional advances, stood at €6.5 million. For the record, equity amounted to −€1.1 million as of June 30, 2025.

Gross financial debt was reduced to €18.6 million, compared to €22.4 million as of December 31, 2025 (−€3.8 million): bond debt stood at €7.5 million (€9.6 million) and bank loans at €8.5 million (€10.2 million). Conditional advances totaled €3.5 million (€4.7 million). Taking into account cash and cash equivalents of €12.3 million, net financial debt amounted to €6.3 million, compared to €17.4 million as of December 31, 2025 (−64%).

Cash Position

Available cash totaled €12.3 million as of June 30, 2026, compared to €5.1 million as of December 31, 2025, and €6.3 million as of June 30, 2025.

Events After the Balance Sheet Date

• BARDA Contract – Amendment 4. Extension of the performance period through June 21, 2030, and additional non-dilutive funding of $4.7 million, bringing the total funding for the development of ZEPIZURE® to $48.0 million. The new scope includes a pediatric clinical trial and a supplementary validation campaign featuring extended stability studies, neither of which are prerequisites for filing the EUA application for the adult indication.

• Liquidity Agreement. Effective July 1, 2026, the liquidity agreement is being administered by Rothschild & Co Global Markets Solutions (Europe) SA, following an internal reorganization of the Rothschild & Co group, with no change to its terms.

• Governance. The Supervisory Board meeting of September 24, 2026, expanded the Executive Board—see the dedicated press release dated September 25, 2026.

Availability of the Half-Year Financial Report

The half-year financial report as of June 30, 2026, will be made available to the public no later than October 30, 2026, on the Company’s website (www.crossject.com), under the “Finance” section.

Forward-Looking Statements

This press release contains forward-looking statements based on assumptions that the Company believes to be reasonable. These statements are subject to risks and uncertainties, including regulatory, industry, and financing risks, many of which are beyond the Company’s control and could result in materially different outcomes. A description of these risks is included in the 2025 Annual Report, available on the Company’s website. These statements are valid only as of the date of this press release, and, unless required by law, the Company undertakes no obligation to update them. This press release was prepared in French and English; in the event of any discrepancy, the French version shall prevail.

Appendix 1 – Half-Year Income Statement (in thousands of euros)

	H1 2026	H1 2025	Change
Operating Revenue	4,798	8,038	−3,240
BARDA Billing	2,532	6,557	−4,025
Capitalized production	1,209	1,483	−274
Production in inventory	−272	−96	−176
Other products	1,329	95	1,234
of which: reversals of provisions	744	10
including proceeds from the sale of fixed assets	567	28
Operating expenses	−13,735	−13,178	−557
Purchases used	−797	−587	−210
Other purchases and external expenses	−5,138	−5,356	218
Personnel expenses	−4,018	−4,048	30
Taxes and duties	−144	−147	3
Depreciation, amortization, and provisions	−2,870	−2,866	−4
of which: inventory write-downs	−374	−236
Other expenses	−769	−173	−596
of which: net book value of disposed fixed assets	−539	–
Operating income	−8,938	−5,139	−3,799
Financial income	−913	−1,143	230
Extraordinary income	–	−141	141
Research tax credit	1,275	1,555	−280
Net income	−8,576	−4,869	−3,707

Appendix 2 – Balance Sheet (in thousands of euros)

	June 30, 2026	12/31/2025	Change
Fixed assets
Research and development expenses	7,256	8,086	−830
Licenses, patents, trademarks, and software	156	0	156
Property, plant, and equipment	2,173	2,429	−256
Assets under construction	3,870	3,487	383
Financial assets	1,158	998	160
Total fixed assets	14,613	15,000	−387
Current assets
Inventories and work in progress	4,088	3,493	595
Trade receivables and related accounts	975	1,975	−1,000
Other receivables (2)	2,893	3,918	−1,025
Cash and cash equivalents	12,345	5,080	7,265
Prepaid and deferred expenses	675	966	−291
Total Current Assets	20,976	15,433	5,543
Total assets	35,589	30,433	5,156

(2) Including advances and prepayments, tax receivables (research tax credit, VAT), and receivables from the sale of fixed assets. The balance sheet is compared to December 31, 2025, the date of the most recent annual financial statements.

Appendix 3 – Balance Sheet Liabilities (in thousands of euros)

	June 30, 2026	12/31/2025	Change
Shareholders’ Equity
Capital	6,002	5,225	777
Share premium	15,926	7,768	8,158
Retained earnings	−11,259	−8,391	−2,868
Net income for the period	−8,576	−10,368	1,792
Capital grants	882	892	−10
Total equity	2,976	−4,874	7,850
Conditional advances	3,505	4,688	−1,183
Provisions for risks and expenses	1,332	1,607	−275
Loans and debt
Bond issues (convertible and straight)	7,538	9,608	−2,070
Loans from credit institutions	8,450	10,211	−1,761
Miscellaneous loans and financial liabilities	2,629	2,629	0
Accounts payable	5,459	4,401	1,058
Tax and social security liabilities	1,636	1,602	33
Other liabilities	1,533	1	1,532
Deferred revenue	532	560	−28
Total Liabilities	27,776	29,011	−1,235
Total equity and liabilities	35,589	30,433	5,156

Appendix 4 – Net Financial Debt and Adjusted Net Financial Debt (in thousands of euros)

	June 30, 2026	12/31/2025	Change
Bond issues	7,538	9,608	−2,070
Bank loans	8,450	10,211	−1,761
Other financial liabilities	2,629	2,629	0
Gross financial debt	18,617	22,448	−3,831
Cash and cash equivalents	−12,345	−5,080	−7,265
Net financial debt	6,272	17,367	−11,095
Amount to be repaid (2025 research tax credit pre-financing) (3)	1,532	–	1,532
Adjusted net financial debt	7,804	17,367	−9,563
Conditional advances	3,505	4,688	−1,183
Adjusted net debt including conditional advances	11,309	22,055	−10,746

Semiannual financial statements that have not been subject to a limited review by the auditors. Amounts rounded to the nearest thousand euros: some totals may not correspond exactly to the sum of their components.

Attachment

• ALCJ_CP_Resultats-S1-2026_FR_V7

Louvain-la-Neuve, Belgium, 25 September 2026, 7 a.m. CEST – IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, today announces it will coordinate the LIFEDESTINY, a new European LIFE project dedicated to tackling one of today’s most persistent environmental challenges: PFAS contamination. The consortium will demonstrate a more sustainable, scalable and cost-effective approach to permanently degrading PFAS across different contaminated matrices.

PFAS, often referred to as “forever chemicals”, are highly persistent, mobile and bioaccumulative substances found in soils, water, ecosystems and waste streams. Current remediation approaches often rely on containment, landfill or incineration, which can be costly, energy-intensive and may not fully eliminate contamination.

An integrated approach spanning the entire treatment chain
LIFEDESTINY (DEmonstration of Sustainable Technologies for INnovative PFAS remediation strategy) aims to prove the feasibility of an integrated treatment process covering the full PFAS remediation chain, from the sourcing and preparation of contaminated materials to PFAS concentration, destruction, analytical validation, neutralisation and potential reuse of treatment residues. The project will address a broad range of liquid and solid waste streams, including industrial wastewater, contaminated soil, sludge and spent granular activated carbon. By combining complementary concentration and destruction technologies, the consortium aims to develop a scalable and energy-efficient alternative to conventional PFAS containment, landfilling and incineration.

A Belgian consortium bringing together the entire value chain
As coordinator, IBA will contribute with its advanced electron beam technology, based on its Rhodotron^® accelerator, to support the destruction of PFAS in contaminated liquid and solid waste streams. This technology will be combined with complementary expertise from project partners.

Alongside IBA, Haemers Technologies brings one of the project’s two PFAS destruction routes for solid matrices, treating contaminated soils and sludges through Krysalis^® thermal desorption while enabling material reuse. NOVOBIOM will develop biosurfactant-based solutions to extract and concentrate PFAS from soil and sludge. DEME Environnement and BESIX Environment will contribute industrial waste streams, remediation expertise, process integration and scale-up capabilities. CEBEDEAU will concentrate PFAS from industrial wastewater and will perform the validation needed to assess treatment efficiency and residue safety. Carmeuse Europe will develop solutions to neutralise fluoride-containing effluents and explore the reuse of treated by-products, while District Cleantech will support stakeholder engagement, dissemination and the project’s pathway towards a future industrial PFAS treatment hub.

The four-year project brings together a Belgian consortium covering the full PFAS treatment value chain, from contaminated waste sourcing and analytical validation to remediation, destruction, neutralisation, reuse and dissemination. Running from 1 September 2026 to 31 August 2030, LIFEDESTINY combines advanced concentration and destruction technologies in an integrated treatment process designed to reduce energy use, CO₂ emissions and hazardous residues compared with conventional approaches.

Catherine Vandenborre, Chief Ventures & Corporate Officer of IBA commented, “LIFEDESTINY complements other initiatives in which IBA is involved to address PFAS contamination and reinforces our ambition to tackle PFAS destruction in a holistic way. By bringing together complementary technologies and expertise across the full treatment value chain, the project reflects IBA’s mission to protect, enhance and save lives — extending the impact of our accelerator expertise to one of today’s most pressing environmental and public health challenges.”

60% European funding
LIFEDESTINY has total eligible project costs of €4,428,018.45 and a maximum EU grant amount of €2,651,675.07, representing a 60% funding rate. Beyond the demonstration phase, the project’s long-term ambition is to lay the foundations for a full-scale PFAS treatment centre or hub capable of industrial-scale deployment.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Climate, Infrastructure and Environment Executive Agency (CINEA). Neither the European Union nor the granting authority can be held responsible for them.

***

 

About IBA

IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as one of the most advanced forms of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,300 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.

IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: www.iba-worldwide.com

For further information, please contact:

Thomas Pevenage Head of Investor Relations +32 10 475 890 investorrelations@iba-group.com

Nathalie van Ypersele Head of Communication and Sustainability Daniel Ernult Corporate Communication Manager +32 10 475 890 communication@iba-group.com

Ad Hoc Announcement Pursuant to Art. 53 LR

Geneva, Switzerland, September 25, 2026 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company developing novel small molecule allosteric modulators for neurological disorders, today announced that it has regained full global rights to all GABAB positive allosteric modulator (PAM) assets discovered under its research collaboration with Indivior UK Limited (“Indivior”). The return of the rights follows Indivior’s rationalization of its research and development activities and the announcement of the planned merger of Indivior’s parent company with Supernus Pharmaceuticals, Inc.

“These GABAB PAM assets reflect years of world-class research in allosteric modulation and build on a biological approach clinically validated by baclofen,” said Tim Dyer, CEO of Addex Therapeutics. “By regaining the rights to the development candidate selected by Indivior, we now have the flexibility to advance our broader GABAB PAM portfolio independently. This includes the returned candidate for substance use disorders and our proprietary candidate in development for chronic cough. We can now evaluate a range of strategic options, including seeking new partnerships in the near term or advancing the programs further before partnering.”

The termination of the collaboration with Indivior provides Addex with full ownership of the returned development candidate and the freedom to pursue therapeutic indications beyond those originally contemplated under the agreement. Combined with Addex’s wholly owned GABAB PAM program for chronic cough, the returned asset gives the company one of the broadest portfolios targeting GABAB receptor biology. The portfolio may have potential applications across substance use disorders, chronic cough, pain, overactive bladder, neurodevelopmental disorders, and other conditions in which modulation of GABAB signaling has demonstrated therapeutic promise.

About GABAB activation
GABA is the main inhibitory neurotransmitter in the central and peripheral nervous systems and acts through two major receptor classes: the ionotropic GABAA receptor and the metabotropic GABAB receptor. GABAB receptors are widely expressed throughout the nervous system and play an important role in regulating neuronal excitability and neurotransmission.

The therapeutic potential of GABAB receptor activation has been clinically demonstrated with baclofen, a selective GABAB receptor agonist that binds to the orthosteric GABA binding site. Baclofen is approved for the treatment of spasticity, including spasticity associated with multiple sclerosis and spinal cord injury. It has also been clinically investigated and used off-label across a broader range of neurological, neuropsychiatric disorders and other conditions including alcohol use disorder and alcohol withdrawal, cocaine use disorder, gastroesophageal reflux disease, and reflux-associated chronic cough.

Although baclofen has demonstrated the therapeutic potential of GABAB receptor activation, its broader use is constrained by aspects of its pharmacological and pharmacokinetics profile. These include sedation and other central nervous system side effects, as well as the potential for reduced efficacy during chronic treatment.

GABAB PAMs offer an alternative approach to enhancing GABAB signaling. Rather than binding to the orthosteric GABA-binding site, PAMs bind to a distinct allosteric site and enhance the receptor’s response to endogenous GABA. This mechanism is intended to preserve the physiological and activity-dependent nature of GABAB receptor signaling. By enhancing the effects of endogenous GABA, GABAB PAMs have the potential to provide greater pathway selectivity, improved tolerability and a reduced propensity for tolerance compared with direct orthosteric agonism. GABAB PAMs therefore represent a promising therapeutic approach for neurological, neuropsychiatric and other disorders in which modulation of inhibitory neurotransmission may provide clinical benefit.

About Addex Therapeutics

Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is a Phase 2 ready asset under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex is developing a GABAB PAM drug candidate for substance use disorders that has successfully completed IND enabling studies and a second GABAB PAM program for chronic cough, which is ready to start IND enabling studies. Addex holds a 20% equity interest in a private spin-out company, Neurosterix US Holdings LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, psychosis and mood-related disorders, and a mGlu7 NAM for mood disorders. In addition, Addex has invested in Stalicla, a private Swiss company pioneering a precision medicine approach for neurodevelopmental and neuropsychiatric disorders.  

Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com.

Contacts:

Tim Dyer Chief Executive Officer Telephone: +41 22 884 15 55 PR@addextherapeutics.com

Mike Sinclair Partner, Halsin Partners +44 (0)7968 022075 msinclair@halsin.com

Addex Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements. 

WISeKey and OISTE.ORG Expand Post-Quantum Root of Trust to Secure the Quantum and AI Era

Quantum-safe Root of Trust designed to provide verifiable identities for AI models, agents, devices and humans, creating a cryptographic foundation for trusted AI

Geneva, Switzerland, September 25, 2026 — WISeKey International Holding Ltd (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, in collaboration with the OISTE.ORG Foundation, announced the expansion of its Quantum Root Key initiative into a Post-Quantum Cryptography (“PQC”) Root of Trust architecture for AI systems, autonomous agents, connected devices and human operators.

The Quantum Root Key was originally generated to address one of the most significant cybersecurity challenges of the coming decade: the potential ability of sufficiently powerful quantum computers to compromise widely deployed public-key cryptographic systems.

However, the rapid development of increasingly autonomous AI systems introduces another fundamental challenge:

How do humans, machines and other AI systems know that an AI model or AI agent is authentic, authorized and operating with trusted software, data and instructions?

WISeKey and OISTE believe that the answer begins with a cryptographically verifiable Root of Trust.

From Root of Trust to Trusted AI

The same Public Key Infrastructure principles that have authenticated websites, devices and digital identities for decades can be extended to support machine-verifiable trust for AI.

Under this architecture, the OISTE/WISeKey Root of Trust can act as the cryptographic trust anchor from which identities and credentials may be issued to AI models, AI agents, devices, organizations and authorized human operators.

Rather than simply trusting an AI because it claims to be a particular model or agent, systems could cryptographically verify its identity and provenance.

This creates a potential chain of trust: Post-Quantum Root of Trust → Organization → AI Model → AI Agent → Device → Transaction

Each element can carry a cryptographically verifiable identity derived from the trusted root.

Securing AI Through Cryptographic Identity

The Root of Trust architecture can support several critical functions required for trusted AI.

• AI Model Identity. AI models can receive cryptographic identities allowing systems to verify which model they are communicating with and whether that identity was issued by an authorized organization.
• Model Integrity and Provenance. Cryptographic signatures and hashes can help verify that model binaries, weights, software components and approved configurations have not been modified since their authorized release.
• AI Agent Authentication. Autonomous agents can authenticate themselves before accessing systems, APIs, financial services, IoT infrastructure or other AI agents.
• Human-to-AI Authorization. Human operators can use trusted digital identities and certificates to establish who is authorized to instruct, modify, deploy or terminate an AI agent.
• AI-to-AI Trust. As autonomous agents increasingly transact with each other, cryptographic credentials can allow one agent to verify the identity and authorization of another before exchanging information or executing transactions.
• Signed AI Actions. High-impact AI actions could be digitally signed, creating evidence of which agent initiated an action, under which identity and authorization.
• Trusted Audit Trails. Signed events can be recorded in tamper-evident or immutable audit systems, creating traceability across the AI lifecycle.

This introduces an important principle for the AI economy: Every AI should have an identity. Every AI action should be attributable. Every critical AI interaction should be verifiable.

Post-Quantum Security at the Foundation

The Root of Trust uses Post-Quantum Cryptography designed to remain secure against both conventional and future quantum attacks.

The architecture incorporates NIST-standardized PQC algorithms including ML-DSA and ML-KEM, together with additional quantum-resistant cryptographic technologies as appropriate to each deployment.

These technologies can be integrated into WISeKey’s trusted infrastructure and Post-Quantum PKI platform, anchoring cryptographic operations within tamper-resistant environments including Hardware Security Modules (HSMs), Trusted Platform Modules (TPMs) and secure semiconductor elements.

The objective is to ensure that the identity infrastructure securing tomorrow’s AI systems does not depend on cryptography that could subsequently become vulnerable to quantum computing.

Hardware Root of Trust: From Cloud AI to the Edge

A critical component of the architecture is connecting digital trust to hardware. Through its subsidiary, SEALSQ Corp (NASDAQ: LAES) (“SEALSQ”), which focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, WISeKey’s semiconductor technology ecosystem can extend the Root of Trust into secure elements, TPMs and post-quantum semiconductor architectures.

This enables an AI workload running on a server, robot, vehicle, industrial controller, satellite or IoT device to establish a cryptographically verifiable relationship between: hardware → firmware → operating environment → AI model → AI agent → authorized user

Such hardware-backed attestation can make it significantly harder for attackers to impersonate legitimate AI agents or silently replace authorized software and models.

A Trust Architecture for AI Supervising AI

The Root of Trust can also become an important component of WISeKey and OISTE’s emerging HUMAN-AI-T framework.

As AI models become more powerful, one potential safety architecture is to use specialized AI systems to supervise the actions of other AI systems while preserving ultimate human governance.

Within this model, a supervisory AI would not merely monitor another model. Both systems would possess independently verifiable cryptographic identities.

The architecture could operate as: OISTE Post-Quantum Root of Trust →Trusted Human Governance → Authenticated AI Supervisor → Authenticated AI Models and Agents → Cryptographically Authorized Actions → Tamper-Evident Audit Trail → Human Escalation / Intervention

The Root of Trust therefore does not attempt to determine whether an AI is “good” or “bad.” Instead, it provides something more fundamental: verifiable identity, integrity, authorization and accountability.

These mechanisms can complement model-level AI safety controls by providing a security layer underneath them.

From “Trust Me” AI to “Verify Me” AI

Today’s AI ecosystem largely depends on organizational and platform trust. Users often cannot independently determine which model generated an output, whether the model was modified, what agent initiated an action, or whether an instruction came from an authorized source.

WISeKey and OISTE’s approach is designed to move toward a “Verify Me” architecture.

An AI system could potentially present a cryptographically verifiable credential demonstrating:

• Who created me.
• Which organization authorized me.
• Which model and version I am running.
• Whether my software environment has been altered.
• What permissions I possess.
• Who authorized the action I am requesting.
• And whether my credentials remain valid.

This cryptographic trust layer could become increasingly important as billions of autonomous AI agents begin communicating, negotiating and transacting across digital networks.

Protecting Critical Infrastructure

The combined PQC and AI Root of Trust architecture is particularly relevant for sectors where autonomous AI decisions could have physical, financial or national-security consequences, including financial services, healthcare, telecommunications, defense, energy, industrial systems, satellites, smart cities, connected vehicles and IoT infrastructure.

Post-Quantum certificates issued through the platform maintain concepts familiar to conventional PKI, including Root and Intermediate Certificate Authorities, defined Key Usages, Certificate Revocation Lists and certificate status mechanisms, while incorporating quantum-resistant cryptographic algorithms.

Building the Trust Layer for the Intelligent Internet

Carlos Moreira, Founder and CEO of WISeKey, stated: “AI is rapidly moving from generating information to taking autonomous actions. In that environment, identity becomes fundamental. Before an AI agent can access infrastructure, communicate with another AI or execute a transaction, we need to know cryptographically who that agent is, who authorized it and whether it has been modified. Our Post-Quantum Root of Trust creates the foundation for this new trust architecture. The objective is simple: AI should not have to be blindly trusted. AI should be cryptographically verifiable. By combining OISTE’s global Root of Trust, WISeKey’s PKI infrastructure and SEALSQ’s secure semiconductor technologies, we believe we can extend digital trust from humans and connected devices to AI models and autonomous agents.”

The convergence of Artificial Intelligence and Quantum Computing represents both an extraordinary technological opportunity and a fundamental cybersecurity challenge.

WISeKey and OISTE believe that the infrastructure protecting this new digital environment must therefore evolve from simply securing communications to establishing identity, provenance, authorization and accountability across humans, machines and AI.

The objective is to create a global trust layer capable of supporting the next generation of the Internet:

• Humans trusting AI.
• AI trusting humans.
• AI trusting AI.
• All anchored in a Post-Quantum Root of Trust.

About WISeKey

WISeKey International Holding Ltd (“WISeKey”, SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA, which specializes in RoT and PKI solutions for secure authentication and identification in IoT, blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) WISe.ART Corp which focuses on trusted blockchain NFTs and operates the WISe.ART marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and houses the development of the SEALCOIN platform.

Each subsidiary contributes to WISeKey’s mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey’s strategic direction and its subsidiary companies, please visit www.wisekey.com.

Forward-Looking Statements

This communication contains forward-looking statements concerning WISeKey International Holding Ltd and/or its subsidiaries (collectively, “WISeKey,” “our” or “us”) and its businesses. Forward-looking statements can be identified by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” and similar expressions. These statements involve known and unknown risks, uncertainties and other factors that could cause WISeKey’s actual results, financial condition, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include: our ability to convert our pipeline into actual sales; the ability to realize WISeKey’s anticipated growth strategies and profitability; the development of post-quantum cryptography products and the potential market for such products; WISeKey’s plans for global customer base expansion; the expansion of the WISeSat project and the QSOC initiative; the timing and expected revenues from the commercial deployment of the QS7001 quantum-resistant semiconductor; the sufficiency of cash to meet liquidity needs; WISeKey’s ability to attract and retain customers; changes in economic conditions; market demand and semiconductor industry conditions; and the risks discussed in WISeKey’s filings with the SEC. WISeKey is providing this communication as of this date and does not undertake to update any forward-looking statements as a result of new information, future events or otherwise.

Statements regarding our business pipeline are based on management’s current estimates of potential revenue opportunities and do not represent backlog or contracted revenue. Pipeline conversion is subject to numerous factors including customer validation, technical integration requirements, certification timelines, and market conditions. There can be no assurance that pipeline opportunities will convert to actual sales or that such conversion will occur within anticipated timeframes.

This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act (“FinSA”), the FinSA’s predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Given the risks and uncertainties described herein, you should not place undue reliance on forward-looking statements as a prediction of actual results.

Press and Investor Contacts

WISeKey International Holding Ltd Company Contact: Carlos Moreira Chairman & CEO Tel: +41 22 594 3000 info@wisekey.com

WISeKey Investor Relations (US)  The Equity Group Inc. Lena Cati Tel: +1 212 836-9611 lena.cati@theequitygroup.com

SHANGHAI, Sept. 24, 2026 (GLOBE NEWSWIRE) — FREELANDER today highlighted the intelligent technology and all-terrain capability of FREELANDER 8 ahead of its Global Brand Launch at Emirates Palace Mandarin Oriental in Abu Dhabi on 29 September. As the British Premium Intelligent All-Terrain Brand prepares to introduce FREELANDER 8 to international audiences, the brand is showcasing how its technologies respond to different driving demands, from desert and gravel environments to paved roads and everyday urban mobility.

At the core of FREELANDER 8’s all-terrain performance is the Intelligent All-Terrain System (i-ATS). Featuring nine modes, the system enables the vehicle to adapt to changing surfaces and driving conditions, extending intelligent control from everyday roads to more demanding terrain.

Working alongside i-ATS, the virtual central differential lock and rear electronic limited-slip differential (e-LSD) enhance stability and traction management on challenging surfaces. Across previous product validations, FREELANDER 8 has been tested in scenarios including deserts, gravel roads, rocky terrain, steep climbs, water crossings and paved roads. Together with i-ATS, the virtual central differential lock and rear e-LSD support the vehicle’s adaptability as surfaces and driving conditions change in diverse global environments.

Beyond all-terrain driving, intelligent technology also extends to the everyday challenges of urban mobility. Super Intelligent Valet Parking (SIVP), offered in selected markets, is designed to support users across a wide range of parking scenarios, from tight urban spaces and complex surroundings to challenging weather conditions. Remote parking and vehicle summon allow users to manage parking tasks through a mobile application, while functions such as space searching and obstacle avoidance further simplify the process. Together, these features bring the principles of Smart Confidence into everyday use.

From desert terrain to urban parking, FREELANDER 8 leverages advanced technology to meet diverse demands of modern mobility. Its Intelligent All-Terrain System (i-ATS) adapts to shifting driving conditions, while SIVP delivers greater convenience for daily journeys. Blending British Craftsmanship, Smart Confidence and All-Terrain Freedom, FREELANDER 8 embodies Beyond the Legend — pairing all-terrain versatility with technology engineered for the real-world needs of Freedom Seekers.

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain brand jointly developed by Chery and Jaguar Land Rover. JLR leads the design and premium DNA, while Chery brings advanced technology and global top-tier supply chain capabilities. The brand is supported by a strong global foundation, including over 5,000 employees, five strategic hubs, and fully integrated capabilities spanning design, R&D, manufacturing, and global operations.

Vincent CHEN
freelander.international@mychery.com
https://www.cheryinternational.com/ 

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/15cdb456-1367-44ae-84bd-09516b6d3d79
https://www.globenewswire.com/NewsRoom/AttachmentNg/2b6324dc-4491-4525-bb15-606d43fa98a8

Toronto, Sept. 24, 2026 (GLOBE NEWSWIRE) — Faircourt Asset Management Inc., as Manager of the Faircourt Fund (CBOE:FGX), is pleased to announce the monthly distribution payable on the Shares of the below listed Fund.  
    

Faircourt Funds	Trading Symbol	Distribution Amount (per share/unit)	Ex-Dividend  Date	Record Date	Payable Date
Faircourt Gold Income Corp.	FGX	$0.034	September 29, 2026	September 30, 2026	October 15, 2026

Faircourt Asset Management Inc. is the Investment Advisor for Faircourt Gold Income Corp. 

This press release is not for distribution in the United States or over United States wire services.

For further information on the Faircourt Funds, please visit www.faircourtassetmgt.com or
please contact 1-800-831-0304.

You will usually pay brokerage fees to your dealer if you purchase or sell Shares of the Fund on the CBOE Canada Exchange or other alternative Canadian trading system (an “exchange”). If the Shares are purchased or sold on an exchange, investors may pay more than the current net asset value when buying Shares of the Fund and may receive less than the current net asset value when selling them.

There are ongoing fees and expenses associated with owning units of an investment fund. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the fund in the public filings available at www.sedar.com. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) — ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx. The gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offering expenses payable by ADARx, are expected to be approximately $446.3 million. In addition, the underwriters have a 30-day option to purchase up to an additional 3,937,500 shares of common stock at the public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on The Nasdaq Global Select Market on September 25, 2026, under the ticker symbol “ADRX.” The offering is expected to close on September 28, 2026, subject to the satisfaction of customary closing conditions.

J.P. Morgan, Morgan Stanley, TD Cowen and UBS Investment Bank are acting as lead book-running managers for the offering. LifeSci Capital is acting as a book-running manager for the offering.

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on September 24, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities. When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, by telephone at 1-866-718-1649, or by email at prospectus@morganstanley.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or UBS Securities LLC, Attention: Equity Syndicate, 11 Madison Avenue, New York, NY 10010 or by email at ol-prospectus-request@ubs.com.

In addition, AbbVie has agreed to purchase, in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended (the Securities Act), a number of shares of ADARx’s common stock that would result in AbbVie owning approximately 4.9% of ADARx’s outstanding shares of common stock following the closing of the initial public offering and the concurrent private placement, at a price of $17.00 per share; provided, however, that in no event would AbbVie purchase more than $100.0 million in shares of common stock. The aggregate gross proceeds to ADARx from the initial public offering and the concurrent private placement, before deducting underwriting discounts and commissions, placement agent fees and other offering and private placement expenses payable by ADARx, are expected to be approximately $535.2 million, excluding any exercise of the underwriters’ option to purchase additional shares of common stock. The concurrent private placement is also scheduled to close on September 28, 2026, subject to the satisfaction of customary closing conditions. The closing of the concurrent private placement is contingent and conditioned upon consummation of the initial public offering. However, the closing of the initial public offering is not contingent on the consummation of the concurrent private placement.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act.

About ADARx Pharmaceuticals

ADARx Pharmaceuticals, Inc. is a late-stage biotechnology company dedicated to transforming cutting-edge science into next-generation siRNA therapeutics. We have developed technology designed to control the expression of specific disease drivers with highly selective RNA targeted therapies with the goal of delivering life-changing treatments for patients with unmet medical needs. ADARx is focused on advancing and expanding a deep pipeline of highly potent, durable and selective RNA-targeted therapeutic candidates, developing product candidates for the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous system and metabolic (obesity) diseases. In addition to our wholly-owned programs, we have entered into a collaboration and license option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, including neuroscience, immunology and oncology.

Forward-Looking Statements

The statements contained in this press release that are not historical facts are forward-looking statements. You can identify forward-looking statements because they contain words such as “believe,” “can,” “estimate,” “expect,” “intend,” “may,” “plans,” “should,” “seeks,” or “will,” or similar expressions which concern ADARx’s strategy, plans, projections or intentions. These forward-looking statements may be included throughout this press release, and include, but are not limited to, statements relating to ADARx’s expected gross proceeds from the initial public offering and concurrent private placement, the expected date for ADARx’s common stock to begin trading on the Nasdaq Global Select Market and the expected closing of the initial public offering and concurrent private placement. By their nature, forward-looking statements are not statements of historical fact or guarantees of future performance and are subject to risks, uncertainties, assumptions or changes in circumstances that are difficult to predict or quantify. ADARx’s expectations, beliefs and projections are expressed in good faith and ADARx believes there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs and projections will result or be achieved and actual results may vary materially from what is expressed in or indicated by the forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this release. ADARx undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.

CONTACT: Contacts

Investors: ir@adarx.com

Media: teri@redhousecomms.com

Blood biomarkers associated with amyloid clearance differ from those associated with cognitive decline in patients receiving lecanemab

FREMONT, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) — Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the publication in The Lancet Neurology of the first longitudinal cohort study to evaluate a broad panel of plasma biomarkers in patients receiving anti-amyloid antibody therapy in real-world clinical practice. The study shows that patients with early symptomatic Alzheimer’s disease exhibit markedly different biological responses during treatment with lecanemab.

Led by investigators at Washington University School of Medicine in St. Louis, the study used Alamar’s NULISAseq™ CNS 120 panel to measure 130 plasma proteins spanning amyloid and tau pathology, inflammation, neurodegeneration and synaptic function. Researchers profiled 2,385 samples from 1,967 participants using just 25 microliters of plasma per sample, including patients receiving lecanemab as part of standard clinical care at the Washington University Memory Diagnostic Center and untreated comparison groups from the Knight Alzheimer Disease Research Center.

“Anti-amyloid therapies are now part of routine care, but until now we have had a very narrow window into what is actually happening biologically in the patients receiving them,” said Carlos Cruchaga, PhD, Professor of Psychiatry and director of the NeuroGenomics and Informatics Center at Washington University School of Medicine, and co-senior author of the study. “Our findings show that Alzheimer’s disease and neurodegeneration biomarkers have unique trajectories that capture specific biological process associated with treatment response.”

The proteins associated with amyloid clearance were largely different from those associated with subsequent cognitive decline. The findings show that amyloid clearance and cognitive response reflect different biological processes, helping explain why clearing amyloid does not produce the same degree of clinical benefit in every patient, a pattern observed both in this cohort and across anti-amyloid trials.

Additionally, among 197 patients treated with lecanemab, 34 of the 130 biomarkers measured significantly changed with the number of infusions received, and they did not all move in the same direction. Among the proteins that most strongly distinguished these patients from controls, the brain-derived forms of tau consistently outperformed the same proteins circulating in the periphery, accounting for four of the top five both before treatment and at the last infusion stage. Separating tau that originates in the brain from its systemic counterpart requires both high specificity for the brain-derived form and the sensitivity to detect it at very low concentrations. Measuring these variants alongside more than 100 additional proteins in a single sample is what allowed the investigators to track pathology and treatment response in one assay.

“This study shows why measuring one or two biomarkers is not enough to understand what is happening during treatment and why ultra-high sensitivity matters,” said Yuling Luo, PhD, founder, CEO and chair of Alamar Biosciences. “Alamar’s precision proteomics platform gives researchers a much richer picture of treatment response and helps us understand why patients with the same diagnosis can have very different outcomes.”

About Alamar Biosciences 
Alamar is a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Leveraging our proprietary NULISA™ technology and the ARGO® HT System, our platform is designed to detect protein biomarkers at extremely low concentrations in blood with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, helping researchers unlock the full spectrum of protein biomarkers across disease states. Learn more at alamarbio.com. 

Forward Looking Statements 
This press release may contain forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the Alamar platform’s capabilities, performance and impact, including its ability to provide richer insights into the treatment response of patients receiving anti-amyloid antibody therapy in real-world clinical practice. Any forward-looking statements in this press release are based on Alamar Biosciences’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Readers are cautioned that actual results could differ materially from those expressed or implied in Alamar Biosciences’ forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to intense competition in the proteomics market, exposure to legal proceedings, regulatory inquiries and other legal matters, failure to develop new assays or instruments, dependence on researchers who rely heavily on government funding, reductions in spending by research and academic institutions, the potential for products to be subject to more onerous regulation by the FDA or other regulatory requirements, the complexity of manufacturing Alamar Biosciences’ instruments and consumables, failure to obtain marketing authorizations for future products that are intended for clinical or diagnostic use, Alamar Biosciences’ ability to protect its intellectual property, and the other risks described in Alamar Biosciences’ filings with the U.S. Securities and Exchange Commission, including its Quarterly Report on Form 10-Q filed with the SEC on , 2026. Alamar Biosciences explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. 

Media Contact: 
Media@alamarbio.com 

Investor Contact: 
Investors@alamarbio.com 

PERTH, Australia, Sept. 24, 2026 (GLOBE NEWSWIRE) — FireFly Metals Ltd (ASX/TSX: FFM) (FireFly or the Company) advises, in accordance with ASX Listing Rule 3.13.1, that the Annual General Meeting (AGM) of the Company will be held on Tuesday, 24 November 2026.

Details of how shareholders can participate in the AGM will be provided with the Notice of Meeting to be released in due course.

An item of business at the AGM will be the election and re-election of directors. In accordance with article 7.5 of the Company’s Constitution, the closing date for receipt of nominations from persons wishing to be considered for election as a director is Tuesday, 6 October 2026.

Any nominations must be received at the Company’s registered office by 5:00pm (AWST) on Tuesday, 6 October 2026.

For further information regarding FireFly Metals Ltd please visit the ASX platform (ASX:FFM) or the Company’s website https://fireflymetals.com.au/.

Authorised by the Board of Directors.

Laura Noonan-Crowe
Company Secretary        
FireFly Metals Ltd

+61 8 9220 9030
info@fireflymetals.com.au
www.fireflymetals.com.au